Lower In-Hospital Mortality With Beta-Blocker Use at Admission in Patients With Acute Decompensated Heart Failure
Overview
Authors
Affiliations
Background It remains unclear whether beta-blocker use at hospital admission is associated with better in-hospital outcomes in patients with acute decompensated heart failure. Methods and Results We evaluated the factors independently associated with beta-blocker use at admission, and the effect of beta-blocker use at admission on in-hospital mortality in 3817 patients with acute decompensated heart failure enrolled in the Kyoto Congestive Heart Failure registry. There were 1512 patients (39.7%) receiving, and 2305 patients (60.3%) not receiving beta-blockers at admission for the index acute decompensated heart failure hospitalization. Factors independently associated with beta-blocker use at admission were previous heart failure hospitalization, history of myocardial infarction, atrial fibrillation, cardiomyopathy, and estimated glomerular filtration rate <30 mL/min per 1.73 m. Factors independently associated with no beta-blocker use were asthma, chronic obstructive pulmonary disease, lower body mass index, dementia, older age, and left ventricular ejection fraction <40%. Patients on beta-blockers had significantly lower in-hospital mortality rates (4.4% versus 7.6%, <0.001). Even after adjusting for confounders, beta-blocker use at admission remained significantly associated with lower in-hospital mortality risk (odds ratio, 0.41; 95% CI, 0.27-0.60, <0.001). Furthermore, beta-blocker use at admission was significantly associated with both lower cardiovascular mortality risk and lower noncardiovascular mortality risk. The association of beta-blocker use with lower in-hospital mortality risk was relatively more prominent in patients receiving high dose beta-blockers. The magnitude of the effect of beta-blocker use was greater in patients with previous heart failure hospitalization than in patients without ( for interaction 0.04). Conclusions Beta-blocker use at admission was associated with lower in-hospital mortality in patients with acute decompensated heart failure. Registration URL: https://www.upload.umin.ac.jp/; Unique identifier: UMIN000015238.
Xie L, Chen J, Li Y, Liu G, Shen J, Li X Front Pharmacol. 2025; 16:1514138.
PMID: 40078276 PMC: 11897012. DOI: 10.3389/fphar.2025.1514138.
Sinardja C, Jagannatha G, de Liyis B, Kosasih A Egypt Heart J. 2024; 76(1):126.
PMID: 39271587 PMC: 11399533. DOI: 10.1186/s43044-024-00558-3.
Sisakian H, Tavaratsyan A Am J Cardiovasc Dis. 2024; 14(2):81-89.
PMID: 38764545 PMC: 11101961. DOI: 10.62347/YGQQ8696.
Cardelli L, Cherbi M, Huet F, Schurtz G, Bonnefoy-Cudraz E, Gerbaud E Pharmaceuticals (Basel). 2023; 16(12).
PMID: 38139866 PMC: 10747751. DOI: 10.3390/ph16121740.
Beta-blocker use and mortality among patients with systolic heart failure and pacemaker rhythm.
Perry A, Maggioni A, Tavazzi L, Levy W ESC Heart Fail. 2023; 10(3):1972-1979.
PMID: 36999245 PMC: 10192283. DOI: 10.1002/ehf2.14353.